Novo Nordisk's recent decline suggests it may be a Buy again, with strong growth prospects in diabetes and obesity treatments ...
CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...
Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...
(BKH) on Wednesday reported fourth-quarter earnings of $98.1 million. On a per-share basis, the Rapid City, South Dakota-based company said it had profit of $1.37. The energy company posted revenue of ...
The company’s shares rose as investors breathed a sigh of relief on strong sales growth and guidance, despite ongoing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback